DISC O V ERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 DEVELOPMENT STAGE & ANTICIPATED MILESTONES COMMERCIAL RIGHTS PROGRAM THERAPEUTIC INDICATION Checkpoint Agonist T S R -042: Anti-PD-1 T S R -022: Anti - TIM-3 T S R -033: Anti-LAG-3 TSR-075: Anti-PD-1/LAG-3 Bispecific C C -90006: Anti-PD-1 Agonist Undisclosed ANB020: Anti - I L -33 ANB019: Anti - I L -36R Severe Adult Eosinophilic Asthma Generalized Pustular Psoriasis Palmo-Plantar Pustular Psoriasis Inflammation Immuno-Oncology Immuno-Oncology Immuno-Oncology Immuno-Oncology Psoriasis Inflammation Mode r ate-to - Se v ere Adult A topic Dermatitis Phase 2a Data Presented at AAD February 2018 Phase 2b To Be Initiated In H1 2018 Phase 2a Top-line Data Announced March 2018 Phase 2a Top-line Data Q3 2018 Initiate Phase 2 2018 Initiate Phase 2 2018 Registration Program Initiated TSR-042 Combination Ongoing Dose Escalation Completed IND Filing H2 2019 IND-Enabling Studies Q1 2018 Ongoing Ongoing Ongoing Moderate-to-Severe Baseline Adult Peanut Allergy Top-Line Data Announced November 2017